MMJ eyes off $5 billion recreational market

Published 05-JUL-2016 12:54 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MMJ PhytoTech (ASX:MMJ) says it could parlay its recent Canadian regulatory approval to produce medical cannabis into the circa $5 billion recreational market on the back of regulatory progress.

The Canadian government recently announced the formation of a taskforce on marijuana legalisation and regulation – with an eye towards potentially legalising cannabis for recreational use.

The task force comprises of experts in law enforcement, medicine, policy, and health care administration – and is set to report back to the government by November this year.

The government has also committed to the introduction of a new regulatory system covering cannabis by the northern hemisphere spring next year.

If the task force recommends legalising cannabis for recreational use, MMJ told its shareholders that it would be in a unique position to take advantage of the market opportunity.

It recently gained approval to grow cannabis for medicinal uses in its Duncan facility in the country – becoming an authorised Licensed Producer under the Marihuana for Medical Purposes Regulations (MMPR).

It said that the requirements for consumer protection and product quality control in the potential new system could be quite similar to MMPR regulations.

There is no guarantee a new system will emerge from the taskforce, though, thus anyone looking at this stock to add to their portfolio should not use this as the basis for any investment decision and should apply caution to that decision.

The new government, led by Prime Minister Justin Trudeau, has affirmed its commitment to legalising cannabis for recreational use in the past – filling MMJ with a measure of confidence that changes will come to pass.

Currently, while growing cannabis for medical purposes is legal – it remains a Schedule II drug under the country’s Controlled Drugs and Substances Act.

Suffice to say, MMJ managing director Andreas Gideon is excited by the possibility of a new market opening up.

“The legalisation of the recreational market is expected to be a major value driver for MMJ and its shareholders, providing strategic access to an emerging market,” he said.

“As we have witnessed in states throughout North America, the legalisation of recreational marijuana has been a key catalyst in allowing regulated cultivators into a growing market.”

Duncan Facility

Located in Duncan, British Colombia, MMJ has invested approximately CAD$8 million ($A8.25 million) on the construction and establishment of the Duncan Facility, which contains high compliance items such as a Level 8 Narcotics Vault and a full service in-house biochemical and analytical laboratory.

MMJ Duncan Facility

Total area at the Duncan Facility is 10,000ft2.

MMJ is awaiting identical MMPR approval for its much larger Lucky Lake facility, which if approved could provide an 1100% increase in production capacity.

MMJ has two other wholly owned subsidiaries separate to United Greeneries, with Swiss based Satipharm which is already generating revenues from its CBD based medical products and Israeli based subsidiary PhytoTech Therapeutics involved in medical cannabis research.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X